Title: Daclizumab
CAS Registry Number: 152923-56-3
CAS Name: Anti-(human interleukin 2 receptor) immunoglobulin G1 (human-mouse monoclonal clone 1H4 g1-chain) disulfide with human-mouse monoclonal clone 1H4 light chain, dimer
Additional Names: humanized anti-Tac; HAT; dacliximab
Manufacturers' Codes: Ro-24-7375
Trademarks: Zenapax (Roche)
Literature References: Humanized monoclonal antibody directed against the a-subunit (p55 alpha, CD25, or Tac subunit) of the human interleukin-2 receptor (IL-2Ra) that is expressed on the surface of activated T lymphocytes. Glycoprotein, mol wt ~150 kDa. DNA sequence is ~90% human origin and ~10% mouse origin. Prepn: C. Queen et al., Proc. Natl. Acad. Sci. USA 86, 10029 (1989). See also: C. L. Queen, H. E. Selick, US 5530101 (1996 to Protein Design Labs). ELISA determn in serum: B. E. Fayer et al., J. Immunol. Methods 186, 47 (1995). Clinical trial in renal transplantation: B. Nashan et al., Transplantation 67, 110 (1999); in cardiac transplantation: A. Beniaminovitz et al., N. Engl. J. Med. 342, 613 (2000). Review of development: J. Hakimi et al. in Antibody Therapeutics, W. J. Harris, J. R. Adair, Eds. (CRC Press, Boca Raton, 1997) pp 277-300; of clinical efficacy in solid organ transplantation: A. M. Wiland, B. Philosophe, Expert Opin. Biol. Ther. 4, 729-740 (2004).
Therap-Cat: Immunosuppressant.
Keywords: Immunosuppressant. |